Group 1 - Fuda Alloy's controlling shareholder Wang Dawu plans to reduce his stake by up to 3% of the company's total shares, amounting to a maximum of 406.34 million shares, due to personal funding needs [1] - ST Songfa's subsidiary signed contracts for the construction of 17 vessels, with a total contract value between 1.6 billion to 1.8 billion USD [2] - Pairui Co. signed a technical cooperation agreement with a university to develop large-capacity power semiconductor devices and related power electronic modules, effective for three years [3] Group 2 - Shuangliang Energy indirectly participates in commercial aerospace projects, supplying heat exchangers for SpaceX's fuel production system, with orders totaling approximately 1.39 million CNY [4] - Hangya Technology plans to issue convertible bonds to raise up to 600 million CNY for various projects, including an intelligent manufacturing base in Malaysia [5] - Yuhua Development is publicly selling assets with a base price of 251 million CNY for residential properties [6] Group 3 - Penghui Energy plans to invest 2.1 billion CNY in a new battery production project in Zhengyang County, Henan Province, focusing on high-performance battery products [7] - Haige Communication's shareholder Yang Haizhou intends to reduce his stake by up to 0.1624% of the company's total shares [8] - Yaoshi Technology's controlling shareholder pledged 5.13% of shares to repay loans, with a pledge period from February 10, 2026, to February 2, 2027 [9][10] Group 4 - Hanyu Pharmaceutical received FDA approval for its drug Acetate Glatiramer Injection, used for treating relapsing multiple sclerosis [11] - Baiyao Tai's GoliMab Injection received EMA approval for various indications, including rheumatoid arthritis and ulcerative colitis [12] - Jiangxi Tungsten Equipment plans to issue A-shares to raise up to 1.882 billion CNY for acquisitions [13] Group 5 - Hesong New Materials expects to recognize asset impairment provisions between 23.6 million to 28.5 million CNY for 2025 [14] - ST Meichen's subsidiary is involved in two major lawsuits with a total amount of approximately 31.9 million CNY [15] - China Coal Energy reported a 7.3% year-on-year decline in coal sales for January 2026, with total sales of 20.05 million tons [16] Group 6 - Yida Co. plans to adjust its epoxy propylene derivative project, reducing the total investment from 845 million CNY to 642 million CNY [17] - Fosun Pharma's subsidiary received approval for a clinical trial of HLX15-SC for multiple myeloma treatment [18][19] - Yinfeng Communication's board members and executives have terminated their share reduction plan [20] Group 7 - Huazhong High-tech has waived its preferential purchase rights for a fund, extending the investment period from three to four years [21] - Warner Pharmaceuticals plans to participate in a national drug procurement program, with expected sales of 176 million CNY [22] - Changling Hydraulic announced a tender offer to acquire 12% of its shares at a price of 35.82 CNY per share [23] Group 8 - ST Chuan Zhi's stock may face delisting due to financial data falling below regulatory thresholds [24] - Tian Pharmaceutical and its subsidiaries are participating in a national drug procurement program, with expected sales of 323 million CNY [25] - China Metallurgical Group signed new contracts worth 73.65 billion CNY in January 2026 [26] Group 9 - Torus plans to invest 21.2 million CNY in a venture capital fund focused on artificial intelligence [27] - Shangwei Co. received a government subsidy of 1.764 million CNY, representing 10.79% of its net profit for 2024 [28] - Hanghua Co. reported a 21.97% decline in net profit for 2025, with total revenue of 1.249 billion CNY [29] Group 10 - Huaxia Bank reported a 1.72% decline in net profit for 2025, with total revenue of 91.914 billion CNY [30] - Guotou Fengle plans to transfer 51% of its stake in Hubei Fengle Ecological Fertilizer to optimize management [31] - Huaru Technology is co-investing in a fund with a total commitment of 20 million CNY [32] Group 11 - Jindike reported a loss of 173 million CNY for 2025, despite a 40.13% increase in revenue [33] - Zhenong Co. announced a 0.52% increase in shares held by a major shareholder [34] - Maike Audi plans to recognize asset impairment provisions of approximately 52.55 million CNY [35] Group 12 - Fuan Pharmaceutical's subsidiary is expected to be selected for a national drug procurement program, with projected sales of 680 million CNY [36] - Rundu Co. is participating in a national drug procurement program, with some products expected to be selected [37] - Changqing Co. has postponed its large-scale die-casting project to March 2027 due to customer requirements [38] Group 13 - Pan Asia Micro透 received a patent for a graphene-based automotive headlight defogging device [39] - Luan An Huan Neng reported a 17.1% increase in raw coal production for January 2026, totaling 5 million tons [40] - Guangji Pharmaceutical received a drug registration certificate for Mecobalamin Tablets [41] Group 14 - Ruifeng New Materials announced the resignation of its deputy general manager for personal reasons [42] - Zhiguang Electric's subsidiary signed a procurement contract for energy storage equipment worth 210.4 million CNY [43] - Youyan Powder Materials reported a 19.41% increase in net profit for 2025 [44] Group 15 - Jincheng reported a 22.2% increase in net profit for 2025, with total revenue of 253 million CNY [46]

长江产业集团将现金全额认购，所购股份36个月内不得转让。资金主要用于偿还借款和补充流动资金， 以优化资本结构，降低资产负债率。截至2025年9月30日，公司资产负债率为62.67%，较高的负债率增 加了债务融资成本。此次定增有助于缓解资金压力，增强抗风险能力与盈利能力。 广济药业主营维生 素B2、B6及医药制剂产品，是全球主要的维生素B2供应商之一。近年来，受市场竞争加剧影响，主要 产品销售价格长期低位，导致业绩持续亏损。财报显示，2023年至2025年，公司净利润连续三年亏损， 且亏损金额持续增长。此外，产线开工率不足、产品市场价格下行等因素也对公司业绩造成不利影响。 据经济观察报-经济观察网 2月11日，广济药业（000952.SZ）公告拟向控股股东长江产业投资集团有限 公司定增募资。 本次发行股票数量不超过94,936,708股，价格为6.32元/股，募集资金总额不超过6亿 元。 市场研究机构预计，2026年开始维生素B2或进入温和增长期。对于广济药业而言，能否依靠控股股东 的驰援扛过周期底部，仍待进一步观察。 ...

Core Viewpoint - Guangji Pharmaceutical (000952.SZ) has proposed a private placement plan to raise up to 600 million yuan, seeking support from its controlling shareholder, Changjiang Industrial Investment Group, amid a projected loss of 399 million to 518 million yuan for 2025 [1][5]. Group 1: Private Placement Details - The private placement will involve a cash subscription by Changjiang Industrial Group, which holds 25.26% of Guangji Pharmaceutical's shares [2]. - The issuance price is set at 6.32 yuan per share, not lower than 80% of the average trading price over the previous 20 trading days [2]. - The number of shares to be issued will not exceed 94,936,708, representing up to 30% of the company's total shares prior to the issuance [2]. Group 2: Company Background and Market Context - Guangji Pharmaceutical specializes in Vitamin B2, B6, and pharmaceutical formulations, being a major global supplier of Vitamin B2, with applications in pharmaceuticals, feed additives, and food additives [3]. - The company has faced continuous net profit losses for three years, with losses increasing from 140 million yuan in 2023 to an expected 399 million to 518 million yuan in 2025, primarily due to low market prices for Vitamin B2 [5][6]. - The demand for vitamins is expected to rise due to improving living standards and health awareness, supported by government policies promoting high-quality vitamin production [3]. Group 3: Financial Health and Future Outlook - As of September 30, 2025, the company's debt-to-asset ratio was 62.67%, indicating high debt financing costs [4]. - The company has been experiencing operational losses due to low production line utilization and declining product prices, leading to asset impairment [6][7]. - Market analysts predict a mild growth phase for Vitamin B2 starting in 2026, with potential stabilization of prices and improved production efficiency due to technological upgrades [7].

广济药业主营维生素B2、B6及医药制剂产品，广泛应用于医药原料药、饲料添加剂和食品添加剂等领 域。公司旗下拥有武穴、孟州等四个生产基地，主导产品包括不同等级的核黄素及其衍生物，以及口服 固体制剂和大输液类产品。 经观健康 广济药业（000952）(000952.SZ)近期公布了一项总额不超过6亿元的定向增发方案，旨在从其控股股东 长江产业投资集团获取资金支持。作为全球维生素B2的主要供应商之一，广济药业近期发布2025年业 绩预告，预计全年将出现3.99亿元至5.18亿元的亏损。 根据广济药业发布的《2026年向特定对象发行A股股票预案》，此次定增的发行对象为湖北省国资旗下 的长江产业集团，该集团目前持有公司25.26%的股份，是其主要股东。本次定增定价基准日为第十一 届董事会第十五次(临时)会议决议公告日，发行价格为6.32元/股，不低于前20个交易日股票均价的 80%。拟发行股份数量上限为94,936,708股，不超过公司总股本的30%，最终数量将在通过深交所审核 并获得证监会注册后由公司董事会与保荐机构协商确定。 自2023年以来，由于维生素B2市场价格持续低迷，广济药业已连续三年出现净利润亏损，且亏损 ...

广济药业（000952）(000952.SZ)发布公告，近日，公司收到国家药品监督管理局核准签发的甲钴胺片 的《药品注册证书》。本次甲钴胺片《药品注册证书》的获批，标志着公司在周围神经疾病治疗领域的 产品布局取得重要进展，为国内患者提供高质量的国产药物选择。 ...

关于取得甲钴胺片药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 近日，湖北广济药业股份有限公司（以下简称"公司"）收到国家药品监 督管理局核准签发的甲钴胺片的《药品注册证书》。现将相关情况公告如下： 一、基本情况 证券代码：000952 证券简称：广济药业 公告编号：2026-023 湖北广济药业股份有限公司 1.药品通用名称：甲钴胺片 8.上市许可持有人名称：湖北广济药业股份有限公司 地址：湖北省武穴市大金镇梅武路 100 号 9.生产企业名称：湖北广济药业股份有限公司 地址：湖北省黄冈武穴市大金广济药业生物产业园 A 区 10.审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说 明书、标签及生产工艺照所附执行。药品生产企业应当符合药品生产质量管理 规范要求方可生产销售。 2.受理号：CYHS2402791 3.证书编号：2026S00402 4.剂型：片剂 5.包装规格：10 片/板×2 板/盒 6.注册分类：化学药品 4 类 7.药品注册标准编号：YBH ...

智通财经APP讯，广济药业(000952.SZ)发布公告，近日，公司收到国家药品监督管理局核准签发的甲钴 胺片的《药品注册证书》。本次甲钴胺片《药品注册证书》的获批，标志着公司在周围神经疾病治疗领 域的产品布局取得重要进展，为国内患者提供高质量的国产药物选择。 ...

本次发行已获得公司第十一届董事会第十五次（临时）会议审议通过，关联董事已回避表决。独立董事 专门会议及审计委员会亦已审议通过相关议案。长江产业集团作为发行对象，其认购行为构成关联交 易。根据协议，长江产业集团认购的股份自本次发行结束之日起将有36个月的限售期。 公司表示，本次定增旨在优化资本结构，降低资产负债率（截至2025年9月30日为62.67%），提升抗风 险能力和持续经营能力。同时，控股股东全额现金认购有助于巩固其控制权，保障公司长期稳定发展。 本次发行方案尚需获得有权国资监管单位批准（如需）、公司股东大会审议通过、深圳证券交易所审核 通过以及中国证券监督管理委员会同意注册后方可实施。 中访网数据 湖北广济药业股份有限公司（证券简称：广济药业，证券代码：000952）于2026年2月11日 发布公告，披露其向特定对象发行A股股票（定增）的相关计划。根据公告，公司拟向控股股东长江产 业投资集团有限公司（长江产业集团）发行不超过94,936,708股股票，募集资金总额不超过人民币 60,000万元。本次发行的定价基准日为董事会决议公告日，发行价格为6.32元/股，不低于定价基准日前 20个交易日股票交易均 ...

广济药业（000952）(000952.SZ)发布2026年向特定对象发行A股股票预案，本次向特定对象发行股票的 发行对象为公司控股股东长江产业集团，发行对象符合法律、法规的规定。本次发行的股票全部采用现 金方式认购。预计募集资金总额不超过6亿元(含本数)，扣除发行费用后用于偿还借款和补充流动资 金。 ...

智通财经APP讯，广济药业(000952.SZ)发布2026年向特定对象发行A股股票预案，本次向特定对象发行 股票的发行对象为公司控股股东长江产业集团，发行对象符合法律、法规的规定。本次发行的股票全部 采用现金方式认购。预计募集资金总额不超过6亿元(含本数)，扣除发行费用后用于偿还借款和补充流 动资金。 ...